Rheumatology 2000; 39: 1383-1389
© 2000 British Society for Rheumatology
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
1 Department of Pharmacoepidemiology and Pharmacotherapy, University of Utrecht, Sorbonnelaan 16, Utrecht, The Netherlands
2 Procter & Gamble Pharmaceuticals, Lovett House, Lovett Road, Staines, UK
3 Sir Mortimer B. Davis Jewish General Hospital, Centre for Clinical Epidemiology and Community Studies, Montreal
4 McGill University, Department of Epidemiology & Biostatistics, Montreal, Canada,
5 MRC Environmental Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK
Objective. This study examined the effects of daily and cumulative oral corticosteroid doses on the risk of fractures.
Methods. Information was obtained from the General Practice Research Database, which contains medical records of general practitioners in England and Wales. The study included 244 235 oral corticosteroid users and 244 235 controls.
Results. Patients taking higher doses (at least 7.5 mg daily of prednisolone or equivalent) had significantly increased risks of non-vertebral fracture [relative rate (RR)=1.44, 95% confidence interval (CI) 1.34–1.54], hip fracture (RR=2.21, 95% CI 1.85–2.64) and vertebral fracture (RR=2.83, 95% CI 2.35–2.40) relative to patients using oral corticosteroids at lower doses (less than 2.5 mg per day). Fracture risk was also elevated among people with higher cumulative exposure to oral corticosteroids over the study period, but this effect was almost wholly removed by adjustment for daily dose, age, gender and other confounding variables.
Conclusions. These findings suggest that the adverse skeletal effects of oral corticosteroids manifest rapidly and are related to daily dose. The level of previous exposure to oral corticosteroids was not a strong determinant of the risk of fracture. Preventive measures against corticosteroid-induced osteoporosis should therefore be instituted as soon after the commencement of glucocorticoid therapy as possible.
KEY WORDS: Osteoporosis, Epidemiology, Glucocorticoids, Fracture, Risk factors.
Correspondence to: C. Cooper, MRC Environmental Epidemiology Unit, Southampton General Hospital, Southampton SO16 6YD, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. F. LEMS Bisphosphonates in Patients with Glucocorticoids: Time for Implementation J Rheumatol, August 1, 2009; 36(8): 1570 - 1572. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meier, M. E. Kraenzlin, M. Bodmer, S. S. Jick, H. Jick, and C. R. Meier Use of Thiazolidinediones and Fracture Risk Arch Intern Med, April 28, 2008; 168(8): 820 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Fujii, T. Hamano, S. Mikami, Y. Nagasawa, Y. Isaka, T. Moriyama, M. Horio, E. Imai, M. Hori, and T. Ito Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1601 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Curtis, A. O. Westfall, J. Allison, A. Becker, M. E. Melton, A. Freeman, C. I. Kiefe, M. MacArthur, T. Ockershausen, E. Stewart, et al. Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users: A Prospective Randomized Trial Arch Intern Med, March 26, 2007; 167(6): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Vondracek and B. A. Hemstreet Retrospective evaluation of systemic corticosteroids for the management of acute exacerbations of chronic obstructive pulmonary disease Am. J. Health Syst. Pharm., April 1, 2006; 63(7): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kristo, R. Jemtland, T. Ueland, K. Godang, and J. Bollerslev Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: A prospective, long-term study Eur. J. Endocrinol., January 1, 2006; 154(1): 109 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Edwards, N. K. Arden, D. Fisher, J. C. Saperia, I. Reading, T. P. Van Staa, and C. Cooper The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database Rheumatology, November 1, 2005; 44(11): 1394 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pisu, N. James, S. Sampsel, and K. G. Saag The cost of glucocorticoid-associated adverse events in rheumatoid arthritis Rheumatology, June 1, 2005; 44(6): 781 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-P. van Staa, P. Geusens, H.A.P. Pols, C. de Laet, H.G.M. Leufkens, and C. Cooper A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids QJM, March 1, 2005; 98(3): 191 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Johannes, G. A. Schneider, T. J. Dube, T. D. Alfredson, K. J. Davis, and A. M. Walker The Risk of Nonvertebral Fracture Related to Inhaled Corticosteroid Exposure Among Adults With Chronic Respiratory Disease Chest, January 1, 2005; 127(1): 89 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I A Campbell, J G Douglas, R M Francis, R J Prescott, and D M Reid Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids Thorax, September 1, 2004; 59(9): 761 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Card, J West, R Hubbard, and R F A Logan Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study Gut, February 1, 2004; 53(2): 251 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Adler and M. C. Hochberg Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs Arch Intern Med, November 24, 2003; 163(21): 2619 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I W Chantler, M W J Davie, S F Evans, and J S Rees Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service Ann Rheum Dis, April 1, 2003; 62(4): 350 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O R Madsen, O H Sorensen, and C Egsmose Bone quality and bone mass as assessed by quantitative ultrasound and dual energy x ray absorptiometry in women with rheumatoid arthritis: relationship with quadriceps strength Ann Rheum Dis, April 1, 2002; 61(4): 325 - 329. [Abstract] [Full Text] [PDF]
|
|